ESMO 2022 Conference Coverage
Lecture Summary - ESMO 2022 on PROs From the Randomized Phase 3 Study DESTINY-Breast04: T-DXd vs. Treatment of Physician’s Choice in HER2-Low mBC
By
ESMO 2022 Conference Coverage
FEATURING
Naoto Ueno
By
ESMO 2022 Conference Coverage
FEATURING
Naoto Ueno
Login to view comments.
Click here to Login
